{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:20:38Z","timestamp":1775647238466,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jpba.2016.02.036","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T17:17:15Z","timestamp":1456679835000},"page":"267-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["HPLC method development, validation, and impurity characterization of a potent antitumor indenoisoquinoline, LMP776 (NSC 725776)"],"prefix":"10.1016","volume":"124","author":[{"given":"Jennie","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingtao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaogang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Euphemia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2016.02.036_bib0005","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jpba.2016.02.036_bib0010","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jpba.2016.02.036_bib0015","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1535-7163.MCT-08-0706","article-title":"The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives","volume":"8","author":"Pommier","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jpba.2016.02.036_bib0020","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1158\/0008-5472.CAN-07-0938","article-title":"Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance","volume":"67","author":"Antony","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2016.02.036_bib0025","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1021\/jm000029d","article-title":"Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors","volume":"43","author":"Cushman","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2016.02.036_bib0030","first-page":"259","article-title":"Indenoisoquinolines NSC 725776 and NSC 724998 inhibit angiogenesis: gamma-H2Ax is potential pharmacologic biomarker","volume":"49","author":"Kaur","year":"2008","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jpba.2016.02.036_bib0035","unstructured":"National Cancer Institute, A phase I study of indenoisoquinolines LMP400 and LMP776 in adults with relapsed solid tumors and lymphomas, ClinicalTrial.gov, Identifier: NCT01051635."},{"key":"10.1016\/j.jpba.2016.02.036_bib0040","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jpba.2010.02.020","article-title":"Liquid chromatography\u2013tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 725776 and NSC 724998","volume":"52","author":"Holleran","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.02.036_bib0045","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00280-015-2722-y","article-title":"Plasma pharmacokinetics of the indenoisoquinoline, topoisomerase I inhibitor, NSC 743400, in rats and dogs","volume":"75","author":"Muzzio","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2016.02.036_bib0050","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1021\/jm060564z","article-title":"Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles","volume":"49","author":"Nagarajan","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851630098X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851630098X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T20:24:34Z","timestamp":1536956674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170851630098X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":10,"alternative-id":["S073170851630098X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2016.02.036","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPLC method development, validation, and impurity characterization of a potent antitumor indenoisoquinoline, LMP776 (NSC 725776)","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2016.02.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}